The Phase 3 Trials of Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

The Phase 3 Trials of Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

Article: Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease (N Engl J Med 2016;375:1946-1960)

Bibliographic Details
Main Author:	Sang Hyoung Park
Format:	Article
Language:	English
Published:	Jin Publishing & Printing Co. 2017-01-01
Series:	The Korean Journal of Gastroenterology
Online Access:	http://www.kjg.or.kr/journal/view.html?doi=10.4166/kjg.2017.69.1.90

Similar Items

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
by: Toshifumi Hibi, et al.
Published: (2017-10-01)

Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
by: Avantika Mishra, et al.
Published: (2018-08-01)

Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
by: Kyunghwan Oh, et al.
Published: (2023-01-01)

Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
by: Kyunghwan Oh, et al.
Published: (2023-04-01)

The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
by: Rintaro Moroi, et al.
Published: (2023-11-01)

Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease
by: Cristina Suárez Ferrer, et al.
Published: (2024-01-01)

Clinical utility of ustekinumab in Crohn’s disease
by: Kotze PG, et al.
Published: (2018-02-01)

Long-term real-world data of ustekinumab in Crohn’s disease: the Stockholm ustekinumab study
by: Francesca Bello, et al.
Published: (2024-04-01)

Clinical Advances in Ustekinumab in the Treatment of Crohn's Disease
by: Xin ZHAO, Yingde WANG
Published: (2022-09-01)

Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis)
by: P. A. Makarchuk, et al.
Published: (2020-10-01)

Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn’s Disease
by: Lorenzo Bertani, et al.
Published: (2023-09-01)

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
by: Deepak P, et al.
Published: (2016-11-01)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
by: An-Yu Chen, et al.
Published: (2019-09-01)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
by: Jairath, V, et al.
Published: (2016)

Ustekinumab and remission in perianal Crohn's disease: A case report
by: C.E. Alcántara-Figueroa, et al.
Published: (2023-10-01)

USTEKINUMAB IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY
by: Paula Cenira Senger de CASTRO, et al.
Published: (2022-11-01)

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
by: Teresa L. Xiao, BA, et al.
Published: (2023-02-01)

Ustekinumab for the treatment of Crohn’s disease: can it find its niche?
by: Ebby G. Simon, et al.
Published: (2016-01-01)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
by: Amanda Hansson-Hedblom, et al.
Published: (2018-08-01)

Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn’s Disease Patients
by: Matthew K. Doherty, et al.
Published: (2018-05-01)

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab
by: Laura Doornekamp, et al.
Published: (2020-08-01)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
by: Syedreza A. Haider, et al.
Published: (2020-10-01)

Enfermedad de Crohn metastásica tratada con ustekinumab
by: Rosa Ballester Sánchez, et al.
Published: (2021-02-01)

Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease
by: Klaudia Miklusiak, et al.
Published: (2023-05-01)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
by: Hisashi Hirayama, et al.
Published: (2022-04-01)

Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease
by: Tuskey A, et al.
Published: (2014-05-01)

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
by: Zhdanava M, et al.
Published: (2024-04-01)

Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease
by: Nathalie Van den Berghe, et al.
Published: (2023-08-01)

Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients
by: Tong Li, et al.
Published: (2020-11-01)

SAPHO Syndrome in Crohn’s Disease Successfully Treated with Ustekinumab: Case Report and Review of the Literature
by: Sara Caporuscio, et al.
Published: (2023-11-01)

A bibliometric and visual analysis of the use of ustekinumab in Crohn’s disease using CiteSpace
by: Yi Chen, et al.
Published: (2024-01-01)

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
by: Jurij Aguiar Zdovc, et al.
Published: (2021-09-01)

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease
by: Jiayin Yao, et al.
Published: (2023-07-01)

Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease
by: Manrong He, et al.
Published: (2021-12-01)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
by: Matsumoto S, et al.
Published: (2018-07-01)

Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis
by: Mohammed Assem Khorshid, et al.
Published: (2022-06-01)

Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
by: Jauregui-Amezaga A, et al.
Published: (2017-11-01)

Real clinical practice of complicated Crohn’s disease treatment with ustekinumab: clinical case presentation
by: P. A. Makarchuk, et al.
Published: (2022-05-01)

Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
by: Anna Viola, et al.
Published: (2021-03-01)

Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Diseasesummary
by: Anna-Maria Globig, et al.
Published: (2021-01-01)